ADDEX THERAPEUTICS LTD (ADXN) Fundamental Analysis & Valuation

NASDAQ:ADXN • US00654J2069

7.12 USD
+0.05 (+0.71%)
Last: Mar 4, 2026, 08:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ADXN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

ADXN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ADXN have multiple concerns. ADXN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. ADXN Profitability Analysis

1.1 Basic Checks

  • ADXN had negative earnings in the past year.
  • In the past year ADXN has reported a negative cash flow from operations.
  • In the past 5 years ADXN reported 4 times negative net income.
  • ADXN had a negative operating cash flow in each of the past 5 years.
ADXN Yearly Net Income VS EBIT VS OCF VS FCFADXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

  • ADXN has a Return On Assets of -77.76%. This is in the lower half of the industry: ADXN underperforms 72.54% of its industry peers.
  • Looking at the Return On Equity, with a value of -95.67%, ADXN is doing worse than 61.66% of the companies in the same industry.
Industry RankSector Rank
ROA -77.76%
ROE -95.67%
ROIC N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ADXN Yearly ROA, ROE, ROICADXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • ADXN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXN Yearly Profit, Operating, Gross MarginsADXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ADXN Health Analysis

2.1 Basic Checks

  • ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ADXN has been increased compared to 1 year ago.
  • The number of shares outstanding for ADXN has been increased compared to 5 years ago.
  • Compared to 1 year ago, ADXN has an improved debt to assets ratio.
ADXN Yearly Shares OutstandingADXN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
ADXN Yearly Total Debt VS Total AssetsADXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -60.14, we must say that ADXN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -60.14, ADXN is not doing good in the industry: 91.71% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.00 indicates that ADXN is not too dependend on debt financing.
  • ADXN's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. ADXN outperforms 60.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -60.14
ROIC/WACCN/A
WACC4.93%
ADXN Yearly LT Debt VS Equity VS FCFADXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 2.01 indicates that ADXN has no problem at all paying its short term obligations.
  • ADXN has a Current ratio of 2.01. This is in the lower half of the industry: ADXN underperforms 60.62% of its industry peers.
  • ADXN has a Quick Ratio of 2.01. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.01, ADXN is in line with its industry, outperforming 46.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
ADXN Yearly Current Assets VS Current LiabilitesADXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ADXN Growth Analysis

3.1 Past

  • The earnings per share for ADXN have decreased strongly by -210.12% in the last year.
  • ADXN shows a decrease in Revenue. In the last year, the revenue decreased by -6.26%.
  • The Revenue for ADXN have been decreasing by -32.07% on average. This is quite bad
EPS 1Y (TTM)-210.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
Revenue 1Y (TTM)-6.26%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-15.07%

3.2 Future

  • The Earnings Per Share is expected to decrease by -17.00% on average over the next years. This is quite bad
  • ADXN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-17%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADXN Yearly Revenue VS EstimatesADXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
ADXN Yearly EPS VS EstimatesADXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. ADXN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADXN. In the last year negative earnings were reported.
  • Also next year ADXN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADXN Price Earnings VS Forward Price EarningsADXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADXN Per share dataADXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ADXN's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADXN Dividend Analysis

5.1 Amount

  • ADXN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADXN Fundamentals: All Metrics, Ratios and Statistics

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (3/4/2026, 8:07:32 PM)

7.12

+0.05 (+0.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-04
Earnings (Next)03-09
Inst Owners1.13%
Inst Owner Change206.53%
Ins Owners5.96%
Ins Owner ChangeN/A
Market Cap8.77M
Revenue(TTM)555.30K
Net Income(TTM)-5.70M
Analysts40
Price TargetN/A
Short Float %0.67%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)15.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.32
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-6.64
EYN/A
EPS(NY)-4.79
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0.58
BVpS6.2
TBVpS6.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.76%
ROE -95.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -60.14
F-Score2
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)0.97%
Cap/Depr(5y)5.54%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-210.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-17%
Revenue 1Y (TTM)-6.26%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-15.07%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y58.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.67%
EBIT Next 3Y5.45%
EBIT Next 5Y5.93%
FCF growth 1Y84.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.91%
OCF growth 3YN/A
OCF growth 5YN/A

ADDEX THERAPEUTICS LTD / ADXN FAQ

What is the fundamental rating for ADXN stock?

ChartMill assigns a fundamental rating of 1 / 10 to ADXN.


What is the valuation status for ADXN stock?

ChartMill assigns a valuation rating of 0 / 10 to ADDEX THERAPEUTICS LTD (ADXN). This can be considered as Overvalued.


Can you provide the profitability details for ADDEX THERAPEUTICS LTD?

ADDEX THERAPEUTICS LTD (ADXN) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ADDEX THERAPEUTICS LTD?

The Earnings per Share (EPS) of ADDEX THERAPEUTICS LTD (ADXN) is expected to decline by -1500% in the next year.